CalibrAlyzer Completes Hundreds of Millions RMB Financing Round to Accelerate Leadership in Multi-Omics Clinical Innovation

VCBeat has learned that Hangzhou Gloria Spectrum Precise Medical Testing Technology Co., Ltd. (“Gloria Spectrum”) recently announced the completion of a new round of financing amounting to hundreds of millions of yuan. The round was led by CICC Jiatai Fund, under CICC Capital, with participation from Fosun Health Capital (under Fosun Pharma), Qishen Venture Capital, Hangzhou Xihu Kechuang Equity Investment Co., Ltd., and CICC Pucheng. China Renaissance served as the exclusive financial advisor for this financing round.This marks another round of financing for Gloria Spectrum, following its tens-of-millions-of-yuan Series B funding completed in 2021.The proceeds from this round of financing will be primarily used for the R&D and regulatory registration of Calibra’s source-innovated instruments and reagents, to accelerate the deployment of its nationwide marketing network, and to expand the company’s production capacity.

As a leading enterprise in the multi-omics innovation sector, Kalu Pu adheres to the mission of "achieving healthy living through innovative diagnostics" and has consistently upheld innovative mass spectrometry applications as its core technology for many years, dedicated toMulti-Omics Data-Driven Product Innovation Strategy, promoting the clinical application and standardization of mass spectrometry and multi-omics in China. Since its establishment, Gloria Spectrum has secured multiple rounds of investment from industry leaders and renowned venture capital firms, including Dian Diagnostics, Boyuan Capital, Hillhouse Ventures, Defu Capital, and Sinowood Capital.

In the year since completing its Series B financing, the company hasKey progress and breakthroughs have been continuously achieved in multiple fields, including multi-omics platform development, R&D and manufacturing of clinical mass spectrometry products, and laboratory standardization solutions.

The company has officially launched its independently developed next-generation CalOmics metabolomics platform. Through strategic layout and collaborations, it has established top-tier domestic capabilities in proteomics and single-cell genomics services. Furthermore, the company has supported its partners in publishing more than 10 papers in high-impact academic journals, including Nature Aging, Cell Reports, Cell Discovery, and the Chinese Journal of Laboratory Medicine, either as co-authors or project undertakers, continuously driving the translation of multi-omics from research tools into clinical value.

The company’s new-generation high-end domestically produced clinical mass spectrometry detection system, CalQuant-S, was officially approved for market launch in March 2022, marking a significant milestone in the localization of high-end clinical mass spectrometry instruments and achieving comprehensive coverage of a closed-loop proprietary product portfolio for standardized total solutions in clinical mass spectrometry. Meanwhile, multiple Class II reagent products independently developed and manufactured by Desaisi Diagnostics, a subsidiary of the company—including those for immunosuppressants, steroid hormones, and fat-soluble vitamins—have been successively approved for market launch, providing healthcare institutions with more reliable and diverse standardized product options for establishing clinical mass spectrometry platforms.

The company authored China’s first expert consensus document on the standardization of clinical mass spectrometry, jointly developed certified reference materials for 25-hydroxyvitamin D in frozen human serum with the National Institute of Metrology, China, and launched CalQMS, the world’s first intelligent quality control software for clinical mass spectrometry laboratories. These achievements have successfully filled multiple gaps in related fields, marking a solid step forward in advancing the standardization of clinical mass spectrometry in China through its own efforts.

Moving forward, Gloria Spectrum will leverage this financing opportunity to continuously increase its investment in the independent research and development of innovative multi-omics diagnostic products, accelerate the registration process for existing self-developed products, and rapidly expand the production capacity of its proprietary clinical mass spectrometry instruments and reagents. By leveraging the company’s diversified channel resources and service system, Gloria Spectrum aims to build a nationwide, world-leading integrated solution for precise diagnosis and treatment based on multi-omics clinical mass spectrometry.

Ms. Liu Huafen, Chairwoman of Gloria SpectrumIndicates：“We extend our sincere gratitude to all new and existing investors, as well as to China Renaissance, for their support. Your recognition serves both as an inspiration and a profound responsibility for us. As a pioneer and practitioner in the standardized application of clinical mass spectrometry in China, Hangzhou Gloria Spectrum Precise Medical Testing Technology Co., Ltd. (Gloria Spectrum) has adhered to its mission of “Achieving Healthy Living through Innovative Diagnostics” since its establishment in 2017. Upholding innovation as our foundation and quality as our cornerstone, we have consistently pursued parallel and integrated development along two core business avenues: multi-omics innovative biomarkers and the industrialization of clinical mass spectrometry.With the launch of CalQuant-S, a new generation of high-end domestically produced clinical mass spectrometry detection systems, Gloria Spectrum has achieved independent productization of standardized solutions for clinical mass spectrometry laboratories, effectively integrating all operational links. Looking ahead, Gloria Spectrum will remain true to its original entrepreneurial vision, further solidifying the industrialization of mass spectrometry, continuously iterating new products, and accelerating the genuine adoption of clinical mass spectrometry technology in real-world hospital settings. Our goal is to make physicians’ work more precise and streamlined, leveraging innovative diagnostic technologies to enhance the health and well-being of the Chinese population. Furthermore, Gloria Spectrum will actively expand into overseas markets, bringing Chinese brands to the global stage.”

Mr. Chen Haibin, Chairman of Dian DiagnosticsIndicates：“This year marks the fifth anniversary of the founding of Gloria Spectrum, as well as the fifth year since Dian Diagnostics formally implemented its mass spectrometry strategy. I am delighted to witness the achievements Gloria Spectrum has attained to date. I believe that Gloria Spectrum will take this milestone as an opportunity to remain true to its original entrepreneurial vision, stay firm in its strategic direction, maintain organizational vitality, and embark on the journey of the next five years. I look forward to Gloria Spectrum grounding itself in a clear grasp of industry development trends, adhering to independent innovation to deliver value to customers, continuously empowering hospital development and advancing translational medicine, and strengthening its integrated ‘service + product + management’ solutions. In doing so, it will truly realize its mission of enhancing the healthy lives of Chinese people through innovative diagnostics. Dian Diagnostics will also continue to promote the practical implementation of its specialized testing and ‘Two Bombs, One Satellite’ business strategies, constantly refine its comprehensive medical diagnostic solutions, and work hand in hand with Gloria Spectrum to advance the integration of multi-omics data and AI-driven clinical diagnosis and treatment.”

Mr. Jiang Shiming, Managing Director of CICC Jiatai Fund, under CICC Capital“It has been stated that clinical mass spectrometry, as one of the primary methodologies in the clinical testing markets of developed countries overseas, has demonstrated significant clinical value in fields such as endocrine metabolism, therapeutic drug monitoring, and nutrition. As products are increasingly commercialized and clinical applications continue to expand, it is poised to become the next rapidly growing market segment within China’s in vitro diagnostics (IVD) industry. Meanwhile, in the era of precision medicine, the value of multi-omics platforms and innovative biomarkers will continue to rise, accelerating the translation and implementation of clinical applications. As a leading enterprise in the fields of clinical mass spectrometry and multi-omics testing, Hangzhou Gloria Spectrum Precise Medical Testing Technology Co., Ltd. (Gloria Spectrum), bolstered by high-quality products, a deeply laid-out pipeline, a highly skilled team, and the substantial resources of Dian Diagnostics, is well-positioned to stand out amidst the industry’s rapid development. We remain firmly optimistic about the prospects of precision medicine and clinical mass spectrometry and will continue to support Gloria Spectrum. We believe that Gloria Spectrum will continuously consolidate its advantages and lead the sustainable development of the industry.”

Ms. Li Fan, Co-CEO of Fosun Health CapitalIt was stated that mass spectrometry, as a powerful tool for precision medicine, holds broad development prospects. As a leader and practitioner in the standardized application of clinical mass spectrometry in China, Gloria Spectrum has always adhered to innovative mass spectrometry applications as its core technology, driving product innovation through multi-omics data. We are highly optimistic about the Gloria Spectrum team led by Professor Liu Huafen, and we believe that their profound technical expertise and industrial experience will surely promote the clinical adoption and standardization of mass spectrometry and multi-omics in China. As an investment fund under Fosun Pharma, we also hope to leverage the R&D strengths and industrial layout of the global Fosun ecosystem to collaborate with Gloria Spectrum in advancing the real-world hospital application of clinical mass spectrometry technologies, thereby improving the health and well-being of the Chinese population through innovative diagnostic solutions.

Mr. Shen Hongquan, Founding Partner of Qishen Venture Capitalstated: “Clinical mass spectrometry and multi-omics have long been our key areas of focus. The core team of Gloria Spectrum has cultivated deep expertise in the industry for many years, possessing rare source innovation capabilities and strong product commercialization prowess within China. As an industry leader, it has made significant contributions to the innovation and industrialization of clinical mass spectrometry and multi-omics in China. We are honored to partner with such a high-quality enterprise and look forward to its continued leadership in innovation, supporting the development of China’s high-end ‘quality’ manufacturing and precision diagnostics industries.”

Ms. Shen Lifen, Chairman of Hangzhou Xihu Kechuang Equity Investment Co., Ltd.Indicates：“Clinical testing based on multi-omics technologies represents a major breakthrough for achieving precision medicine. We will continue to provide comprehensive support in funding, policy, and industry aspects to fully advance the R&D, production, registration, certification, and commercialization strategies of KaluPu’s new products. Xihu Kechuang Venture Capital is optimistic about KaluPu’s potential for translational applications of multi-omics data-driven products in global clinical research, disease diagnosis and treatment, and drug development, especially given the trends of continuous technological optimization and cost reduction. Moving forward, Xihu Kechuang Venture Capital will further strengthen its empowerment of high-quality sci-tech innovation enterprises in Xihu District, focusing on facilitating the implementation of the Greater Health Initiative, supporting the growth of biopharmaceutical technology companies, and providing more precise solutions for clinical diagnosis, treatment, and prognosis.”

Mr. Xie Yijing, Managing Director and Head of the Healthcare and Life Sciences Group at China Renaissancestated: “We are honored to have assisted Calibra in completing this round of financing. As a leader in multi-omics innovative diagnostics and the industrialization of clinical mass spectrometry in China, Calibra is one of the very few benchmark enterprises in the country that has established an end-to-end capability spanning from early biomarker discovery to clinical validation, product translation, and commercial implementation. We are optimistic about multi-omics becoming the next major growth frontier in precision diagnosis and treatment, and we look forward to Calibra, as a frontrunner in this field, continuing to make greater breakthrough contributions to China’s independent innovation in precision medicine.”

CICC Capital Management Co., Ltd. (hereinafter referred to as “CICC Capital”) is a wholly-owned private equity investment management subsidiary of China International Capital Corporation Limited (hereinafter referred to as “CICC”). Serving as CICC’s platform for private equity fund business, CICC Capital manages CICC’s domestic and overseas private equity fund operations. The types of funds under its management include RMB corporate equity investment funds, funds of funds (FOFs), real estate funds, infrastructure funds, and USD corporate equity investment funds, making it a leading comprehensive alternative asset investment management platform in China with international influence. As of the end of 2021, CICC Capital had cumulative assets under management exceeding RMB 400 billion and employed a professional investment management team of over 400 members.

Fosun Health Capital, a controlling subsidiary of Fosun Pharma, serves as the management company for its affiliated funds. It manages multiple RMB-denominated funds focused on investments in the healthcare sector, including angel funds for holding and incubation, venture capital (VC) funds for minority equity investments, and private equity (PE) funds targeting growth-stage companies. These underlying funds primarily invest in various sub-sectors of healthcare, such as biopharmaceuticals, high-end medical devices, in vitro diagnostics (IVD), life sciences, and diagnostic and therapeutic technologies, achieving capital appreciation through diverse exit strategies. By leveraging the R&D strengths and industrial layout of Fosun’s global ecosystem, Fosun Health Capital provides full-lifecycle empowerment to portfolio companies, driving their development.

Qishen Venture Capital is an emerging investment fund focused on “innovative drugs and innovative medical devices,” with the vision of “helping Chinese pharmaceutical innovation enterprises go global and give back to society.” The core team members possess over 26 years of industry experience and have led investments totaling tens of billions of yuan. Its historical portfolio includes numerous high-quality companies such as Borui Medicine (688166), Haichuang Pharmaceutical (688302), Jingjie Bio, Changfeng Pharmaceutical, Xiantong Pharmaceutical, Weimai Medical, Tongxin Medical, Lijin Biologics, and Stermune.

Hangzhou Xihu Kechuang Equity Investment Co., Ltd. (hereinafter referred to as “Xihu Kechuang Tou”) is a state-owned enterprise directly under the Hangzhou Xihu District People’s Government. It manages and operates the Xihu District Science and Technology Innovation Direct Investment Fund, with a scale of RMB 1 billion, focusing on investing in high-quality enterprises in Xihu District in fields such as cloud computing, artificial intelligence, Internet of Things, aerospace information, biomedicine, intelligent manufacturing, and cultural creativity, thereby empowering their growth and development.